Transcription factor 7-like 2 (T-cell specific, HMG-box), also known asTCF7L2 orTCF4, is aprotein acting as atranscription factor that, in humans, is encoded by theTCF7L2gene.[5][6] The TCF7L2gene is located on chromosome 10q25.2–q25.3, contains 19exons.[7][8] As a member of theTCF family, TCF7L2 can form a bipartite transcription factor and influence several biological pathways, including theWnt signalling pathway.[9]
TCF7L2 is a transcription factor influencing thetranscription of severalgenes thereby exerting a large variety of functions within the cell. It is a member of the TCF family that can form a bipartite transcription factor (β-catenin/TCF) alongside β-catenin.[9] Bipartite transcription factors can have large effects on theWnt signalling pathway.[9] Stimulation of the Wnt signaling pathway leads to the association of β-catenin withBCL9, translocation to the nucleus, and association with TCF7L2,[21] which in turn results in the activation of Wnt target genes. The activation of the Wnt target genes specifically represses proglucagon synthesis in enteroendocrine cells.[9][8] The repression of TCF7L2 usingHMG-box repressor (HBP1) inhibits Wnt signalling.[9] Therefore, TCF7L2 is an effector in the Wnt signalling pathway. TCF7L2's role in glucose metabolism is expressed in many tissues such as gut, brain, liver, and skeletal muscle. However, TCF7L2 does not directly regulateglucose metabolism inβ-cells, but regulates glucose metabolism in pancreatic and liver tissues.[22] That said, TCF7L2 directly regulates the expression of multiple transcription factors, axon guidance cues, cell adhesion molecules and ion channels in the thalamus.[23]
The TCF7L2 gene encoding the TCF7L2 transcription factor, exhibits multiple functions through its polymorphisms and thus, is known as a pleiotropic gene. Type 2 diabetes T2DM susceptibility is exhibited in carriers of TCF7L2 rs7903146C>T[24][25] and rs290481T>C[25] polymorphisms.[24][25] TCF7L2 rs290481T>C polymorphism, however, has shown no significant correlation to the susceptibility togestational diabetes mellitus (GDM) in a Chinese Han population, whereas the T alleles of rs7903146[25] and rs1799884[10] increase susceptibility to GDM in the Chinese Han population.[25][10] The difference in effects of the different polymorphisms of the gene indicate that the gene is indeed pleiotropic.
TheTCF7L2 gene, encoding the TCF7L2 protein, is located on chromosome 10q25.2-q25.3. The gene contains 19 exons.[7][8] Of the 19 exons, 5 arealternative.[8] The TCF7L2 protein contains 619amino acids and its molecular mass is 67919Da.[26] TCF7L2's secondary structure is ahelix-turn-helix structure.[27]
TCF7L2 is primarily expressed in brain (mainly in thediencephalon, including especially high in thethalamus[23][28][29]), liver, intestine and fat cells. It does not primarily operate in the β-cells in the pancreas.[30]
Several single nucleotide polymorphisms within the TCF7L2 gene have been associated with type 2 diabetes. Studies conducted by Ravindranath Duggirala and Michael Stern at TheUniversity of Texas Health Science Center at San Antonio were the first to identify stronglinkage for type 2 diabetes at a region onChromosome 10 in Mexican Americans[31] This signal was later refined by Struan Grant and colleagues atDeCODE genetics and isolated to the TCF7L2 gene.[32] The molecular and physiological mechanisms underlying the association of TCF7L2 with type 2 diabetes are under active investigation, but it is likely that TCF7L2 has important biological roles in multiple metabolic tissues, including the pancreas, liver and adipose tissue.[30][33] TCF7L2 polymorphisms can increase susceptibility to type 2 diabetes by decreasing the production ofglucagon-like peptide-1 (GLP-1).[9]
TCF7L2 modulatespancreatic islet β-cell function strongly implicating its significant association withGDM risk.[10] T alleles of rs7903146[25] and rs1799884[10] TCF7L2 polymorphisms increase susceptibility toGDM in the Chinese Han population.[25][10]
TCF7L2 plays a role incolorectal cancer.[17] Aframeshift mutation of TCF7L2 provided evidence that TCF7L2 is implicated in colorectal cancer.[34][35] The silencing of TCF7L2 inKM12 colorectal cancer cells provided evidence that TCF7L2 played a role inproliferation andmetastasis of cancer cells in colorectal cancer.[17]
Variants of the gene are most likely involved in many other cancer types.[36] TCF7L2 is indirectly involved inprostate cancer through its role in activating thePI3K/Akt pathway, a pathway involved in prostate cancer.[37]
Single nucleotide polymorphisms (SNPs) in TCF7L2 gene have shown an increase in susceptibility toschizophrenia in Arab, European and Chinese Han populations.[citation needed] In the Chinese Han population, SNP rs12573128[14] in TCF7L2 is the variant that was associated with an increase in schizophrenia risk. This marker is used as a pre-diagnostic marker for schizophrenia.[14] TCF7L2 has also been reported as a risk gene inautism spectrum disorder[38] and has been linked to it in recent large-scale genetic studies.[15][16]
The mechanism behind TCF7L2's involvement in the emergence of neurodevelopmental disorders is not fully understood, as there have been few studies characterizing its role in brain development in detail. It was shown that during embryogenesis TCF7L2 is involved in the development of fish-specifichabenula asymmetry inDanio rerio,[39][40] and that the dominant negative TCF7L2 isoform influences cephalic separation in the embryo by inhibiting the posteriorizing effect of the Wnt pathway.[41] It was also shown that inTcf7l2 knockout mice the number of proliferating cells in cortical neural progenitor cells is reduced.[42] In contrast, no such effect was found in the midbrain.[43]
More recently it was shown that TCF7L2 plays a crucial role in both the embryonic development and postnatal maturation of the thalamus through direct and indirect regulation of many genes previously reported to be important for both processes.[23] In late gestation TCF7L2 regulates the expression of many thalamus-enriched transcription factors (e.g.Foxp2,Rora,Mef2a,Lef1,Prox1), axon guidance molecules (e.g.Epha1,Epha4,Ntng1,Epha8) and cell adhesion molecules (e.g.Cdh6,Cdh8, Cdhr1). Accordingly, a total knockout ofTcf7l2 in mice leads to improper growth of thalamocortical axons, changed anatomy and improper sorting of the cells in the thalamo-habenular region.[23] In the early postnaral period TCF7L2 starts to regulate the expression of many genes necessary for the acquisition of characteristic excitability patterns in the thalamus, mainly ion channels, neurotransmitters and their receptors and synaptic vescicle proteins (e.g.Cacna1g,Kcnc2,Slc17a7,Grin2b), and an early postnatal knockout ofTcf7l2 in mouse thalamus leads to significant reduction in the number and frequency of action potentials generated by thethalamocortical neurons.[23] The mechanism that leads to the change in TCF7L2 target genes between gestation and early postnatal period is unknown. It is likely that a perinatal change in the proportion of TCF7L2 isoforms expressed in the thalamus is partially responsible.[28] Abnormalities in the anatomy of the thalamus and the activity of its connections to the cerebral cortex are frequently detected in patients with schizophrenia[44][45][46][47] and autism.[48][49][50][51] Such abnormalities could arise from developmental aberrations in patients with unfavorable mutations of TCF7L2, further strengthening the link between TCF7L2 and neurodevelopmental disorders.
TCF7L2 is downstream of theWNT/β-catenin pathways. The activation of the WNT/β-catenin pathways have been associateddemyelination inmultiple sclerosis.[18] TCF7L2 is unregulated during earlyremyelination, leading scientists to believe that it is involved inremyelination.[18] TCF7L2 could act in dependence or independent of the WNT/β-catenin pathways.[18]
Variations of the protein encoding gene are found in rats, zebra fish, drosophila, and budding yeast.[59] Therefore, all of those organisms can be used as model organisms in the study of TCF7L2 function.
^Hansen T, Ingason A, Djurovic S, Melle I, Fenger M, Gustafsson O, et al. (July 2011). "At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia".Biological Psychiatry.70 (1):59–63.doi:10.1016/j.biopsych.2011.01.031.PMID21414605.S2CID42205809.
^abcTorres S, García-Palmero I, Marín-Vicente C, Bartolomé RA, Calviño E, Fernández-Aceñero MJ, et al. (January 2018). "Proteomic Characterization of Transcription and Splicing Factors Associated with a Metastatic Phenotype in Colorectal Cancer".Journal of Proteome Research.17 (1):252–264.doi:10.1021/acs.jproteome.7b00548.hdl:10261/160082.PMID29131639.
^abChen Y, Zhao Y, Li YB, Wang YJ, Zhang GZ (January 2018). "Detection of SNPs of T2DM susceptibility genes by a ligase detection reaction-fluorescent nanosphere technique".Analytical Biochemistry.540–541 (Supplement C):38–44.doi:10.1016/j.ab.2017.11.003.PMID29128291.
^Sun P, Xiong H, Kim TH, Ren B, Zhang Z (February 2006). "Positive inter-regulation between beta-catenin/T cell factor-4 signaling and endothelin-1 signaling potentiates proliferation and survival of prostate cancer cells".Molecular Pharmacology.69 (2):520–531.doi:10.1124/mol.105.019620.PMID16291872.S2CID10148857.
Maruyama K, Sugano S (January 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides".Gene.138 (1–2):171–174.doi:10.1016/0378-1119(94)90802-8.PMID8125298.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (October 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library".Gene.200 (1–2):149–156.doi:10.1016/S0378-1119(97)00411-3.PMID9373149.
Omer CA, Miller PJ, Diehl RE, Kral AM (March 1999). "Identification of Tcf4 residues involved in high-affinity beta-catenin binding".Biochemical and Biophysical Research Communications.256 (3):584–590.Bibcode:1999BBRC..256..584O.doi:10.1006/bbrc.1999.0379.PMID10080941.
Giannini AL, Vivanco MM, Kypta RM (March 2000). "Analysis of beta-catenin aggregation and localization using GFP fusion proteins: nuclear import of alpha-catenin by the beta-catenin/Tcf complex".Experimental Cell Research.255 (2):207–220.doi:10.1006/excr.1999.4785.PMID10694436.
Duval A, Busson-Leconiat M, Berger R, Hamelin R (2000). "Assignment of the TCF-4 gene (TCF7L2) to human chromosome band 10q25.3".Cytogenetics and Cell Genetics.88 (3–4):264–265.doi:10.1159/000015534.PMID10828605.S2CID13148464.
Duval A, Rolland S, Tubacher E, Bui H, Thomas G, Hamelin R (July 2000). "The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines".Cancer Research.60 (14):3872–3879.PMID10919662.
Graham TA, Ferkey DM, Mao F, Kimelman D, Xu W (December 2001). "Tcf4 can specifically recognize beta-catenin using alternative conformations".Nature Structural Biology.8 (12):1048–1052.doi:10.1038/nsb718.PMID11713475.S2CID33878077.
Poy F, Lepourcelet M, Shivdasani RA, Eck MJ (December 2001). "Structure of a human Tcf4-beta-catenin complex".Nature Structural Biology.8 (12):1053–1057.doi:10.1038/nsb720.PMID11713476.S2CID24798619.
